Alivus Life Sciences has released its Investor Presentation for the first quarter of FY27 (Q1 FY27). The presentation details the company’s financial performance, including revenue, EBITDA, and PAT figures. It also highlights key growth drivers such as the non-GPL business performance and strategic initiatives for future capacity expansion and R&D capabilities.
Alivus Life Sciences Unveils Q1 FY27 Investor Presentation
Alivus Life Sciences has submitted its Investor Presentation for the quarter ending June 30, 2026 (Q1 FY27). The comprehensive document provides an overview of the company’s operational and financial highlights, strategic direction, and future growth plans. This presentation aligns with the company’s commitment to transparent disclosure and investor engagement.
Q1 FY27 Financial Highlights
The company reported a Revenue of ₹6,404 million for Q1 FY27. EBITDA stood at ₹2,341 million with an EBITDA Margin of 36.6%, showing a significant year-over-year growth of 650 bps. Profit After Tax (PAT) was ₹1,601 million, accompanied by a Net Margin of 25.0%, indicating healthy profitability. The presentation also notes strong free cash flow generation of ₹901 Mn.
Segmental Performance and Growth Drivers
The Investor Presentation details performance across key segments. The non-GPL business demonstrated strong growth, with revenues increasing 27.6% QoQ and 26.5% YoY. Conversely, the GPL business witnessed a de-growth of 52.6% YoY due to inventory rationalization, though recovery is expected in H2 FY27. The CDMO business saw a 3.8% YoY growth in Q1 FY27.
Strategic Outlook and Capacity Expansion
Alivus Life Sciences outlined its strategy focused on Gx API business growth through new product launches and geographical expansion, alongside enhancing its CDMO capabilities. The company is undertaking significant capacity expansions, including greenfield expansion at its Solapur facility and brownfield expansion in Ankleshwar and Dahej. R&D capabilities are being strengthened with a focus on flow chemistry, complex products, and oncology research.
Market and Return Indicators
The presentation also covers market and therapeutic area mix, with Regulated Markets contributing 83% of Q1 FY27 revenues. Healthy return indicators were highlighted, with ROICE tracking at approximately 32%. Fixed Assets Turnover (FATR) was reported at 2.2 times. The company also emphasized its strong balance sheet, with cash and cash equivalents totaling ₹8,802 Mn as of June 30, 2026.
Source: BSE
